KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Eli Lilly (LLY) over the last 14 years, with Q3 2025 value amounting to $899.7 million.

  • Eli Lilly's Shares Outstanding (Diluted Average) fell 58.56% to $899.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $899.7 million, marking a year-over-year decrease of 58.56%. This contributed to the annual value of $904.1 million for FY2024, which is 8.58% up from last year.
  • As of Q3 2025, Eli Lilly's Shares Outstanding (Diluted Average) stood at $899.7 million, which was down 58.56% from $900.2 million recorded in Q2 2025.
  • Eli Lilly's 5-year Shares Outstanding (Diluted Average) high stood at $912.4 million for Q1 2021, and its period low was $899.7 million during Q3 2025.
  • Over the past 5 years, Eli Lilly's median Shares Outstanding (Diluted Average) value was $904.2 million (recorded in 2024), while the average stood at $905.1 million.
  • Per our database at Business Quant, Eli Lilly's Shares Outstanding (Diluted Average) plummeted by 78.98% in 2022 and then grew by 21.04% in 2024.
  • Eli Lilly's Shares Outstanding (Diluted Average) (Quarter) stood at $911.7 million in 2021, then fell by 0.77% to $904.6 million in 2022, then fell by 0.15% to $903.3 million in 2023, then grew by 0.09% to $904.1 million in 2024, then decreased by 0.48% to $899.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $899.7 million for Q3 2025, versus $900.2 million for Q2 2025 and $900.6 million for Q1 2025.